Sugi Predict

Sugi Predict / Targets / MME

MME

Neprilysin · P08473 · MME on Sugi Atlas →

96,103 patent compounds predicted against MME, 53,683 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL388863 SCHEMBL388863 0.59 20/20
SCHEMBL391627 SCHEMBL391627 0.56 18/20
Candoxatrilat Candoxatrilat (SCHEMBL123669) 1.00 16/20
Candoxatrilat Candoxatrilat (SCHEMBL389958) 1.00 16/20
Candoxatrilat Candoxatrilat (SCHEMBL389959) 1.00 16/20
Lbq-657 Lbq-657 (SCHEMBL391633) 1.00 14/20
SCHEMBL186665 SCHEMBL186665 0.39 14/20
Candoxatril Candoxatril (SCHEMBL121666) 1.00 12/20
Candoxatril Candoxatril (SCHEMBL392920) 1.00 12/20
SCHEMBL692 SCHEMBL692 0.71 12/20
SCHEMBL400158 SCHEMBL400158 0.54 12/20
SCHEMBL29046 SCHEMBL29046 0.68 11/20
SCHEMBL29983 SCHEMBL29983 0.68 11/20
SCHEMBL30889 SCHEMBL30889 0.68 11/20
SCHEMBL389938 SCHEMBL389938 0.69 10/20
SCHEMBL389939 SCHEMBL389939 1.00 9/20
SCHEMBL18591 SCHEMBL18591 0.64 9/20
SCHEMBL27205 SCHEMBL27205 0.54 9/20
SCHEMBL386632 SCHEMBL386632 0.51 9/20
SCHEMBL516 SCHEMBL516 0.73 8/20

Clinical trials — most relevant to MME by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Pharmacological Reduction of Functional, Ischemic Mitral REgurgitation PHASE4COMPLETED
Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3 PHASE4COMPLETED
Circulating NEP and NEP Inhibition Study in Heart Failure With Preserved Ejection Fraction PHASE4COMPLETED
Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Valve Regurgitation PHASE4COMPLETED
Dapagliflozin Effect on FunctiOnal Mitral Regurgitation and Myocardial Fibrosis (DEFORM) PHASE4UNKNOWN
Comparing the Effects of Spironolactone With Chlortalidone on LV Mass in Patients With CKD PHASE4UNKNOWN
Study of Sacubitril/ValsarTan on MyocardIal OxygenatioN and Fibrosis in Heart Failure With Preserved Ejection Fraction PHASE3WITHDRAWN
The Effects of Sacubitril/Valsartan Compared to Valsartan on LV Remodelling in Asymptomatic LV Systolic Dysfunction After MI PHASE3COMPLETED
Efficacy of Candesartan on Symptomatic Heart Failure in Treating Diabetic and Hypertensive Patients. PHASE3COMPLETED
Effect of Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction PHASE3NOT_YET_RECRUITING
Lifestyle and Pharmacological Interventions in Hypertrophic Cardiomyopathy PHASE2/PHASE3COMPLETED
Effect of Strict Blood Pressure Control and ACE-Inhibition on Progression of Chronic Renal Failure in Pediatric Patients PHASE3COMPLETED
Sacubitril/Valsartan vs Lifestyle in Hypertrophic Cardiomyopathy PHASE2COMPLETED
Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted PHASE2COMPLETED
A Research Study on the Effects of NNC0537-1482 in Participants With Heart Failure PHASE1RECRUITING
A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart Failure PHASE1COMPLETED
Effects of Different Forms of a Natural Heart Hormone on Blood Pressure and Fluid Balance in Healthy Volunteers EARLY_PHASE1COMPLETED
Neutral Endopeptidase for Early Detection of Acute Kidney Injury After Cardiac Surgery nanCOMPLETED
Clearance of Vasoactive Metabolites With Blood Purification nanRECRUITING
Impact of Sacubitril/Valsartan on Quality of Life and Mortality of CKD vs Non-CKD in Heart Failure Patients nanCOMPLETED
Is Sacubitril-valsartan Superior to Dapagliflozin in Improving Myocardial Function Performance nanCOMPLETED
Evaluate the Safety and Preliminary Efficacy of EXG110 in Subjects With Fabry Disease nanRECRUITING
The Fabrazyme® and Arbs and ACE Inhibitor Treatment (FAACET) Study nanCOMPLETED
Use of Telemonitoring to Facilitate Heart Failure Medication Titration nanUNKNOWN
Clinical Potassium Pilot Study nanCOMPLETED
Physical Rehabilitation for Older Patients With Acute Heart Failure With Preserved Ejection Fraction nanRECRUITING
Secondary Use of PARALLEL-HF Data nanCOMPLETED
The Comparative Effectiveness Between ARNI and ACE Inhibitor/ARB Medication in Patient With HFrEF nanUNKNOWN
LBBP as Initial Therapy in Patients With Non-ischemic Heart Failure and LBBB nanACTIVE_NOT_RECRUITING
Efficacy and Safety of Angiotensin II Use in Coronavirus Disease(COVID)-19 Patients With Acute Respiratory Distress Syndrome nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a MME binder may also engage these)

ProteinNameSimilarity
Q5RE69 — 1.000 Q5RE69 →
Q61391 — 1.000 Q61391 →
P07861 — 1.000 P07861 →
P08049 — 1.000 P08049 →
Q8IS64 — 0.999 Q8IS64 →
A0A0B4K692 — 0.998 A0A0B4K692 →
Q18673 — 0.997 Q18673 →
Q9JLI3 — 0.997 Q9JLI3 →
P97739 — 0.995 P97739 →
O16796 — 0.995 O16796 →
Q9W5Y0 — 0.994 Q9W5Y0 →
O44857 — 0.993 O44857 →
ECE1 Endothelin-converting enzyme 1 0.993 landscape →
P42891 — 0.993 P42891 →
Q4PZA2 — 0.992 Q4PZA2 →
W4VS99 — 0.992 W4VS99 →
P42893 — 0.989 P42893 →
P0C1T0 — 0.989 P0C1T0 →
MMEL1 Membrane metallo-endopeptidase-like 1 0.987 landscape →
Q22523 — 0.987 Q22523 →
ACE2 Angiotensin-converting enzyme 2 0.986 landscape →
Q9W436 — 0.985 Q9W436 →
B2RQR8 — 0.985 B2RQR8 →
Q8R0I0 — 0.984 Q8R0I0 →
A5HUI5 — 0.984 A5HUI5 →
Q58DD0 — 0.982 Q58DD0 →
P97449 — 0.982 P97449 →
ENPEP Glutamyl aminopeptidase 0.982 landscape →
P15684 — 0.982 P15684 →
F1N476 — 0.981 F1N476 →